JP6743135B2 - 抗ウィルス性テトラヒドロフラン誘導体 - Google Patents

抗ウィルス性テトラヒドロフラン誘導体 Download PDF

Info

Publication number
JP6743135B2
JP6743135B2 JP2018511491A JP2018511491A JP6743135B2 JP 6743135 B2 JP6743135 B2 JP 6743135B2 JP 2018511491 A JP2018511491 A JP 2018511491A JP 2018511491 A JP2018511491 A JP 2018511491A JP 6743135 B2 JP6743135 B2 JP 6743135B2
Authority
JP
Japan
Prior art keywords
compound
weeks
formula
hcv
another aspect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018511491A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018529671A5 (enExample
JP2018529671A (ja
Inventor
チャウ，ジャクリーン
チェン，ホイ−ジュイ・ジェイ
デゴイー，デイビッド・エイ
ハートゥング，ジョン
イデ，ネイサン
カルソッド，ビクラム
クリューガー，アラン・シー
クー，イー−イン
リー，トンメイ
ランドルフ，ジョン・ティー
ワグナー，ロルフ
ボイト，エリック
ハルボーセン，ジェフ・ティー
マービン，クリストファー・シー
ブラウン，ブライアン・エス
マルティネス，スティーブン・アール
シュレスタ，アヌルパ
ヘイマン，ハワード・アール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of JP2018529671A publication Critical patent/JP2018529671A/ja
Publication of JP2018529671A5 publication Critical patent/JP2018529671A5/ja
Application granted granted Critical
Publication of JP6743135B2 publication Critical patent/JP6743135B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2018511491A 2015-09-02 2016-09-01 抗ウィルス性テトラヒドロフラン誘導体 Expired - Fee Related JP6743135B2 (ja)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US201562213378P 2015-09-02 2015-09-02
US62/213,378 2015-09-02
US201562242136P 2015-10-15 2015-10-15
US62/242,136 2015-10-15
US201562253426P 2015-11-10 2015-11-10
US62/253,426 2015-11-10
US201662294449P 2016-02-12 2016-02-12
US62/294,449 2016-02-12
US201662296801P 2016-02-18 2016-02-18
US62/296,801 2016-02-18
US201662321538P 2016-04-12 2016-04-12
US62/321,538 2016-04-12
US201662327087P 2016-04-25 2016-04-25
US62/327,087 2016-04-25
US201662351038P 2016-06-16 2016-06-16
US62/351,038 2016-06-16
US201662363640P 2016-07-18 2016-07-18
US62/363,640 2016-07-18
US201662375029P 2016-08-15 2016-08-15
US62/375,029 2016-08-15
PCT/US2016/049873 WO2017040766A1 (en) 2015-09-02 2016-09-01 Anti-viral tetrahydrofurane derivatives

Publications (3)

Publication Number Publication Date
JP2018529671A JP2018529671A (ja) 2018-10-11
JP2018529671A5 JP2018529671A5 (enExample) 2019-11-21
JP6743135B2 true JP6743135B2 (ja) 2020-08-19

Family

ID=56926317

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018511491A Expired - Fee Related JP6743135B2 (ja) 2015-09-02 2016-09-01 抗ウィルス性テトラヒドロフラン誘導体

Country Status (7)

Country Link
US (2) US9676797B2 (enExample)
EP (1) EP3344642A1 (enExample)
JP (1) JP6743135B2 (enExample)
CN (1) CN108350016B (enExample)
CA (1) CA2997170A1 (enExample)
MX (1) MX2018002707A (enExample)
WO (1) WO2017040766A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10011629B2 (en) * 2015-05-01 2018-07-03 Cocrystal Pharma, Inc. Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
MX2018002707A (es) * 2015-09-02 2018-08-01 Abbvie Inc Derivados de tetrahidrofurano antivirales.
WO2018093717A1 (en) * 2016-11-17 2018-05-24 Abbvie Inc. Compositions and methods for treating hcv infection
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
CN111836818B (zh) * 2018-01-10 2023-10-31 纽科利制药公司 氨基磷(膦)酸缩醛和磷(膦)酸缩醛化合物
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
CN109762040A (zh) * 2019-01-14 2019-05-17 歌礼生物制药(杭州)有限公司 一种核苷类ns5b聚合酶抑制剂的制备方法
EP3999519A4 (en) 2019-07-17 2023-08-16 Nucorion Pharmaceuticals, Inc. CYCLIC DEOXYRIBONUCLEOTIDE COMPOUNDS
EP4139319A4 (en) 2020-04-21 2024-06-19 Ligand Pharmaceuticals, Inc. BENZYLOXY-PHOSPH(ON)ATE COMPOUNDS
WO2021216427A1 (en) 2020-04-21 2021-10-28 Ligand Pharmaceuticals, Inc. Nucleotide prodrug compounds
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
US5246924A (en) 1987-09-03 1993-09-21 Sloan-Kettering Institute For Cancer Research Method for treating hepatitis B virus infections using 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil
SE8802687D0 (sv) 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
US6060592A (en) 1990-01-11 2000-05-09 Isis Pharmaceuticals, Inc. Pyrimidine nucleoside compounds and oligonucleoside compounds containing same
US6060542A (en) 1997-05-16 2000-05-09 Shell Oil Company Bitumen compositions and a process for their preparation
EP1058686B1 (en) 1998-02-25 2006-11-02 Emory University 2'-fluoronucleosides
PY0111577A (es) 2000-05-23 2017-01-02 Idenix Cayman Ltd Métodos y composiciones para el tratamiento del virus de la hepatitis c
US6596700B2 (en) 2000-05-26 2003-07-22 Idenix Pharmaceuticals Inc. Methods of treating hepatitis delta virus infection with β-L-2'-deoxy-nucleosides
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
AP2006003708A0 (en) 2000-05-26 2006-08-31 Idenix Cayman Ltd Methods and compositions for treating flavivirusesand pestiviruses
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
AU2001296542B2 (en) * 2000-10-02 2007-10-25 Emory University Triptolide analogs for the treatment of autoimmune and inflammatory disorders
JP2004533406A (ja) 2000-10-18 2004-11-04 フアーマセツト・リミテツド ウイルス感染症および異常細胞増殖を治療するための修飾ヌクレオシド
US8481712B2 (en) 2001-01-22 2013-07-09 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
US7105499B2 (en) 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
SI1355916T1 (sl) 2001-01-22 2007-04-30 Merck & Co Inc Nukleozidni derivati kot inhibitorji RNA-odvisne RNA virusne polimeraze
AU2002330154A1 (en) 2001-09-28 2003-04-07 Centre National De La Recherche Scientifique Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
CA2488842A1 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. Carbocyclic nucleoside analogs as rna-antivirals
JP2005530843A (ja) 2002-06-21 2005-10-13 メルク　エンド　カムパニー　インコーポレーテッド Ｒｎａ依存性ｒｎａウィルスポリメラーゼ阻害剤としてのヌクレオシド誘導体
CN1678326A (zh) 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
RU2005118421A (ru) 2002-11-15 2006-01-20 Айденикс (Кайман) Лимитед (Ky) 2'-разветвленные нуклеозиды и мутация flaviviridae
PL377287A1 (pl) 2002-12-12 2006-01-23 Idenix (Cayman) Limited Sposób wytwarzania 2'-rozgałęzionych nukleozydów
WO2004084453A2 (en) * 2003-03-20 2004-09-30 Microbiologica Quimica E Farmaceutica Ltd. METHODS OF MANUFACTURE OF 2'-DEOXY-β-L-NUCLEOSIDES
BRPI0419345B8 (pt) 2003-05-30 2021-05-25 Gilead Pharmasset Llc uso do (2’r)-2’-desoxi-2’-flúor-2’-c-metil nucleosídeo e de uma composição farmacêutica que o compreende
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
CA2589935A1 (en) 2004-12-09 2006-06-15 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
PA8852101A1 (es) 2008-12-08 2010-07-27 Medivir Ab Nucleótidos uracil ciclopropílicos
TWI583692B (zh) * 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
EA020031B1 (ru) 2009-06-11 2014-08-29 Эббви Бахамаз Лтд. Противовирусные соединения
US9790252B2 (en) 2009-07-01 2017-10-17 Cornell University 2-fluorinated riboses and arabinoses and methods of use and synthesis
EP2789614B1 (en) * 2009-08-11 2017-04-26 Bristol-Myers Squibb Company Azaindazoles as Btk kinase modulators and use thereof
US9700560B2 (en) 2009-11-16 2017-07-11 University Of Georgia Research Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
CL2011000716A1 (es) * 2010-03-31 2012-04-20 Gilead Pharmasset Llc Formas cristalinas 1 6 de (s)-isopropil-2-(((s)-(((2r.3r.4r.5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-4-fluoro-3-hidroxi-4-metil tetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato; composicion y combinacion farmaceutica; y su uso para tratar una infeccion por el virus de la hepatitis c.
WO2012040126A1 (en) * 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
WO2012075140A1 (en) 2010-11-30 2012-06-07 Pharmasset, Inc. Compounds
US9156874B2 (en) * 2011-01-03 2015-10-13 Nanjing Molecular Research, Inc. Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs
CN103842369A (zh) 2011-03-31 2014-06-04 埃迪尼克斯医药公司 用于治疗病毒感染的化合物和药物组合物
EP2696681B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
ES2744587T3 (es) * 2011-04-13 2020-02-25 Gilead Sciences Inc Análogos de N-nucleósido de pirimidina 1-sustituidos para un tratamiento antiviral
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US20130143835A1 (en) * 2011-12-05 2013-06-06 Medivir Ab HCV Polymerase Inhibitors
UA111761C2 (uk) * 2011-12-20 2016-06-10 Рібосаєнс Ллс 2',4'-дифтор-2'-метилзаміщені нуклеозидні похідні як інгібітори реплікації phk вірусу гепатиту c
US9708357B2 (en) * 2011-12-20 2017-07-18 Riboscience, LLC 4′-azido, 3′-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication
WO2013187978A1 (en) * 2012-06-16 2013-12-19 Nanjing Molecular Research, Inc. Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs
CN102751200B (zh) 2012-06-29 2015-06-10 京东方科技集团股份有限公司 薄膜晶体管、阵列基板及其制造方法
US20140065101A1 (en) * 2012-08-31 2014-03-06 Novartis Ag 2'-Branched Nucleosides for Treatment of Viral Infections
SG11201502750UA (en) 2012-10-08 2015-06-29 Idenix Pharmaceuticals Inc 2'-chloro nucleoside analogs for hcv infection
AR092959A1 (es) 2012-10-17 2015-05-06 Merck Sharp & Dohme Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
GEP201706757B (en) 2012-12-21 2017-10-25 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
US10034893B2 (en) 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
BR112015025766A2 (pt) 2013-04-12 2017-10-17 Achillion Pharmaceuticals Inc derivado de nucleosídeo altamente ativo para o tratamento de hcv
HK1224229A1 (zh) 2013-06-26 2017-08-18 Alios Biopharma, Inc. 取代的核苷，核苷酸及其类似物
UA117375C2 (uk) 2013-09-04 2018-07-25 Медівір Аб Інгібітори полімерази hcv
DK3043803T3 (da) 2013-09-11 2022-08-01 Univ Emory Nukleotid- og nucleosidsammensætninger og deres anvendelse
JP6562908B2 (ja) 2013-10-11 2019-08-21 ヤンセン バイオファーマ インク． 置換ヌクレオシド、置換ヌクレオチドおよびその類似体
EP3057976A1 (en) * 2013-10-17 2016-08-24 Medivir Ab Hcv polymerase inhibitors
WO2015077360A2 (en) * 2013-11-20 2015-05-28 Idenix Pharmaceuticals, Inc. Cyclopentane and cyclopentene nucleoside analogs for the treatment of hcv
EP3074399A1 (en) 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
US20160346198A1 (en) * 2014-02-05 2016-12-01 Merck Sharp & Dohme Corp. Novel disintegration systems for pharmaceutical dosage forms
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
CN106536538A (zh) 2014-04-24 2017-03-22 共晶制药股份有限公司 用于治疗黄病毒家族病毒和癌症的2’‑双取代核苷类似物
WO2016069975A1 (en) 2014-10-31 2016-05-06 Cocrystal Pharma, Inc. 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
US10011629B2 (en) 2015-05-01 2018-07-03 Cocrystal Pharma, Inc. Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
MX2018002707A (es) * 2015-09-02 2018-08-01 Abbvie Inc Derivados de tetrahidrofurano antivirales.

Also Published As

Publication number Publication date
EP3344642A1 (en) 2018-07-11
US20170057981A1 (en) 2017-03-02
CN108350016B (zh) 2021-07-27
CA2997170A1 (en) 2017-03-09
JP2018529671A (ja) 2018-10-11
WO2017040766A1 (en) 2017-03-09
US9676797B2 (en) 2017-06-13
US20180022763A1 (en) 2018-01-25
US10053474B2 (en) 2018-08-21
CN108350016A (zh) 2018-07-31
MX2018002707A (es) 2018-08-01

Similar Documents

Publication Publication Date Title
US10053474B2 (en) Anti-viral compounds
US9732111B2 (en) 2′-alkynyl substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US9242988B2 (en) 2′-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
CN115844896B (zh) 治疗沙粒病毒科和冠状病毒科病毒感染的方法
US9457039B2 (en) 2′-disubstituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
JP6495822B2 (ja) Ｈｃｖ感染用の２’−クロロヌクレオシド類似体
TW201429983A (zh) 經取代之核苷、核苷酸及其類似物
CA2818853A1 (en) 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
TW201418274A (zh) ２’－甲基經取代之核苷衍生物及其用於治療病毒疾病之使用方法
EP2598498B1 (en) Hetero-bicyclic derivatives as hcv inhibitors
US10899788B2 (en) Cyclic phosphate substituted nucleoside compounds and methods of use thereof for the treatment of viral diseases
WO2016134054A1 (en) Anti-viral compounds
US20200179428A1 (en) Cyclic phosphate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2017040895A1 (en) Anti-viral compounds
US20190192548A1 (en) Use of cyclic phosphate substituted nucleoside derivativesfor the treatment of viral diseases
WO2017040896A1 (en) Anti-viral compounds
WO2016134056A1 (en) Anti-viral compounds
WO2017040892A1 (en) Anti-viral compounds
WO2016182935A1 (en) Anti-viral compounds
WO2016182934A1 (en) Anti-viral compounds
WO2016134053A1 (en) Anti-viral compounds
WO2016182939A1 (en) Anti-viral compounds
WO2016182936A1 (en) Anti-viral compounds
WO2017040899A2 (en) Anti-viral compounds
WO2017040889A1 (en) Anti-viral compounds

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191004

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20191004

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20191029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200501

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200630

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200729

R150 Certificate of patent or registration of utility model

Ref document number: 6743135

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees